In a Phase 1/2 trial MRTX849, an investigational KRAS G12C inhibitor has demonstrated clinical activity, including objective responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Although a maximum targeted dose has not yet been...